Role of bacterial infections in allograft rejection

Expert Review of Clinical Immunology

Volumn 4, Issue 2, 2008, Pages 281-293

  Ahmed, Emily B ^a   Alegre, Maria Luisa ^a   Chong, Anita S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bacteria; Infection; Innate immunity; Pattern recognition receptor; Rejection; Transplantation; Type 1 interferon

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN A; INTERFERON; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ALLOIMMUNITY; BACTERIAL INFECTION; CHRONIC GRAFT REJECTION; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; VIRUS INFECTION;

EID: 46149091296     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.2.281     Document Type: Review

References (131)

1. Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl. Immunol. 13(2), 117-130 (2004).
2. LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J. Immunol. 178(12), 7503-7509 (2007).
3. McLaughlin K, Wu C, Fick G et al. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 74(6), 813-816 (2002).
4. Reinke P, Fietze E, Ode-Hakim S et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 344(8939-8940), 1737-1738 (1994).
5. Sageda S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant. 2(9), 850-856 (2002).
6. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am. J. Transplant. 3(2), 116-120 (2003).
7. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect. Dis. 2(9), 539-549 (2002).
8. Lopez C, Simmons RL, Mauer SM et al. Association of renal allograft rejection with virus infections. Am. J. Med. 56(3), 280-289 (1974).
9. Hale DA. Basic transplantation immunology. Surg. Clin. North Am. 86(5), 1103-1125 (2006).
10. Bruno DA, Dhanireddy KK, Kirk AD. Challenges in therapeutic strategies for transplantation; where now from here? Transpl. Immunol. 15(2), 149-155 (2005).
11. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346(8), 580-590 (2002).
12. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev. 10(1), 86-124 (1997).
13. Rubin RH. Temporal aspects of transplant infectious disease. Transpl. Infect. Dis. 5(2), 63-64 (2003).
14. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med. 338(24), 1741-1751 (1998).
15. Singh N. Infections in solid organ transplant recipients. Curr. Opin. Infect. Dis. 13(4), 343-347 (2000).
16. Sharpies LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J. Heart Lung Transplant. 21(2), 271-281 (2002).
17. El-Gamel A, Sim E, Hasleton P et al. Transforming growth factor β (TGF-β) and obliterative bronchiolitis following pulmonary transplantation. J. Heart Lung Transplant. 18(9), 828-837 (1999).
18. Wilkes DS, Egan TM, Reynolds HY. Lung transplantation: opportunities for research and clinical advancement. Am. J. Respir. Crit. Care Med. 172(8), 944-955 (2005).
19. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J. Heart Lung Transplant. 21(3), 297-310 (2002).
20. Norgaard MA, Andersen CB, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation? Eur. J. Cardiothorac. Surg. 14(3), 311-318 (1998).
21. Girgis RE, Tu I, Berry GJ et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J. Heart Lung Transplant. 15(12), 1200-1208 (1996).
22. Heng D, Sharples LD, McNeil K et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J. Heart Lung Transplant. 17(12), 1255-1263 (1998).
23. Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart - lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg. 110(1), 4-13 (1995).
24. Glanville AR, Gencay M, Tamm M et al. Chlamydia pneumoniae infection after lung transplantation. J. Heart Lung Transplant. 24(2), 131-136 (2005).
25. Husain S, Kahane S, Friedman MG et al. Simkania negevensis in bronchoalveolar lavage of lung transplant recipients: a possible association with acute rejection. Transplantation 83(2), 138-143 (2007).
26. Wiebe K, Fraund S, Steinmuller C, Steinhoff G. Rat cytomegalovirus and Listeria monocytogenes infection enhance chronic rejection after allogenic rat lung transplantation. Transpl. Int. 18(10), 1166-1174 (2005).
27. Reyes J, B ueno J, Kocoshis S et al. Current status of intestinal transplantation in children. J. Pediatr. Surg. 33(2), 243-254 (1998).
28. Sigurdsson L, Reyes J, Kocoshis SA et al. Bacteremia after intestinal transplantation in children correlates temporally with rejection or gastrointestinal lymphoproliferative disease. Transplantation 70(2), 302-305 (2000).
29. Berg RD. Promotion of the translocation of enteric bacteria from the gastrointestinal tracts of mice by oral treatment with penicillin, clindamycin, or metronidazole. Infect. Immun. 33(3), 854-861 (1981).
30. Deitch EA, Maejima K, Berg R. Effect of oral antibiotics and bacterial overgrowth on the translocation of the GI tract microflora in burned rats. J. Trauma 25(5), 385-392 (1985).
31. Wells CL. Colonization and translocation of intestinal bacterial flora. Transplant. Proc. 28(5), 2653-2656 (1996).
32. Cicalese L, Sileri P, Green M et al. Bacterial translocation in clinical intestinal transplantation. Transplantation 71(10), 1414-1417 (2001).
33. Rubin RH. Infectious disease complications of renal transplantation. Kidney Int. 44(1), 221-236 (1993).
34. Nampoory MR, Johny KY, Costandy JN et al. Infection related renal impairment: a major cause of acute allograft dysfunction. Exp. Clin. Transplant. 1(1), 60-64 (2003).
35. Giral M, Pascuariello G, Karam G et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int. 61(5), 1880-1886 (2002).
36. Kamath NS, John GT, Neelakantan N, Kirubakaran MG, Jacob CK. Acute graft pyelonephritis following renal transplantation. Transpl. Infect. Dis. 8(3), 140-147 (2006).
37. Audard V, Amor M, Desvaux D et al. Acute graft pyelonephritis: a potential cause of acute rejection in renal transplant. Transplantation 80(8), 1128-1130 (2005).
38. Ozdemir BH, Sar A, Uyar P et al. Posttransplant tubulointerstitial nephritis: clinicopathological correlation. Transplant. Proc. 38(2),466-469 (2006).
39. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin. Transplant. 19(2), 230-235 (2005).
40. Menlikoglu KO, Keven K, Sengul S et al. Urinary tract infections following renal transplantation: a single-center experience. Tranplant. Proc. 39(10), 3131-3134 (2007).
41. Abbott KC, Swanson SJ, Richter ER et al. Late urinary tract infection after renal transplantation in the United States. Am. J. Kidney Dis. 44(2), 353-362 (2004).
42. Tveit DJ, Hypolite IO, Poropatich RK et al. Hospitalizations for bacterial pneumonia after renal transplantation in the United States. J. Nephrol. 15(3), 255-262 (2002).
43. Xia D, Yan LN, Xu L et al. Postoperative severe pneumonia in adult liver transplant recipients. Transplant. Proc. 38(9), 2974-2978 (2006).
44. Garbino J, Romand JA, Pittet D et al. Infection and rejection in liver transplant patients: a 10-year Swiss single-centre experience. Swiss Med. Nkly 135(39-40), 587-593 (2005).
45. Berger N, Guggenbichler S, Steurer W et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect. Dis. 6, 127 (2006).
46. Abbott KC, Oliver JD 3rd, Hypolite I et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am. J. Nephrol. 21(2), 120-127 (2001).
47. Winters GL, Costanzo-Nordin MR, O'Sullivan EJ et al. Predictors of late acute orthotopic heart transplant rejection. Circulation 80(5 Pt 2), III106-III110 (1989).
48. Kirk AD. Induction immunosuppression. Transplantation 82(5), 593-602 (2006).
49. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin. Transplant. 21(2), 149-158 (2007).
50. Adams AB, Pearson TC, Larsen CP. Heterologous; immunity: an overlooked barrier to tolerance. Immunol. Rev. 196, 147-160 (2003).
51. Brehm MA, Markees TG, Daniels KA et al. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J. Immunol. 170(8), 4077-4086 (2003).
52. Welsh RM, Markees TG, Woda BA et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J. Virol. 74(5), 2210-2218 (2000).
53. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today, 13(1), 11-16 (1992).
54. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
55. Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin. Immunol. 10(5), 349-350 (1998).
56. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
57. Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6 (4), 435-442 (2000).
58. Guillot L, Balloy V, McCormack FX et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J. Immunol. 168(12), 5989-5992 (2002).
59. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 168(10), 5233-5239 (2002).
60. Leadbetter EA, Rifkin IR, Hohlbaum AM et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416(6881), 603-607 (2002).
61. Mollen KP, Anand RJ, Tsung A et al. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26(5), 430-437 (2006).
62. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol. 164(2), 558-561 (2000).
63. Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin. Immunopathol. 26(3), 231-246 (2005).
64. Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. 195(1), 99-111 (2002).
65. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
66. Kabelitz D, Medzhitov R. Innate immunity - cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19(1), 1-3 (2007).
67. Christopher K, Mueller TF, Ma C, Liang Y, Perkins DL. Analysis of the innate and adaptive phases of allograft rejection by cluster analysis of transcriptional profiles. J. Immunol. 169(1), 522-530 (2002).
68. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation 73(6), 853-861 (2002).
69. He H, Stone JR, Perkins DL. Analysis of differential immune responses induced by innate and adaptive immunity following transplantation. Immunology 109(2), 185-196 (2003).
70. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin. Immunol. 17(4), 338-344 (2005).
71. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26(8), 447-454 (2005).
72. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 442(7098), 39-44 (2006).
73. O'Riordan M, Yi CH, Gonzales R, Lee KD, Portnoy DA. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc. Natl Acad. Sci. USA 99(21), 13861-13866 (2002).
74. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol 5(10), 987-995 (2004).
75. Kawai T, Akira S. TLR signaling. Cell Death Differ. 13(5), 816-825 (2006).
76. Schnare M, Barton GM, Holt AC et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2(10), 947-950 (2001).
77. + T cells and enables CpG oligodeoxynucleotide- mediated costimulation. Immunity 25(5), 783-793 (2006).
78. + T cell survival. J. Immunol. 172(10), 6065-6073 (2004).
79. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 19(1), 39-45 (2007).
80. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J. Clin. Invest. 111(10), 1571-1578 (2003).
81. Goldstein D. Role of MyD88 and Trif in acute allograft rejection: glass half full or empty? Eur. J. Immunol 36(10), 2820 (2006).
82. Tesar BM, Zhang J, Li Q, Goldstein DR. Th1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am. J. Transplant. 4(9), 1429-1439 (2004).
83. Walker WE, Nasr IW. Camirand G et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 177(8), 5307-5316 (2006).
84. Chen I. Wang T, Zhou P et al. TLR engagement prevents transplantation tolerance. Am. J. Transplant. 6(10), 2282-2291 (2006).
85. Thornley TB, Brehm MA, Markees TG et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J. Immunol. 176(3), 1561-1570 (2006).
86. + T cell-mediated suppression by dendritic cells. Science 299(5609), 1033-1036 (2003).
87. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5(5), 508-515 (2004).
88. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 25(3), 373-381 (2006).
89. Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25(2), 187-191 (2000).
90. Palmer SM, Burch LH, Davis RD et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am. J. Respir Crit. Care Med 168(6), 628-632 (2003).
91. Palmer SM, Burch LH, Trindade AJ et al. Innate immunity influences long-term outcomes after human lung transplant. Am. J. Respir. Crit. Care Med. 171(7), 780-785 (2005).
92. Palmer SM, Klimecki W, Yu L et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am. J. Transplant. 7(3), 693-699 (2007).
93. Ducloux D, Deschamps M, Yannaraki M et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int. 67(6), 2454-2461 (2005).
94. Nogueira E, Ozaki KS, Macusso GD et al. Incidence of donor and recipient Toll-like receptor-4 polymorphisms in kidney transplantation. Transplant. Proc. 39(2), 412-414 (2007).
95. Palmer SM, Burch LH, Mir S et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin. Transplant. 20(l), 30-36 (2006).
96. Methe H, Zimmer E, Grimm C, Nabauer M, Koglin J. Evidence for a role of Toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 78(9), 1324-1331 (2004).
97. Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, MDA-5, and inhibit its activation of the IFN-β promoter. Proc. Natl Acad. Sci. USA 101(49), 17264-17269 (2004).
98. Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355-383 (2005).
99. Kang DC, Gopalkrishnan RV, Wu Q et al. MDA-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Prooc. Natl. Acad. Sci. USA 99(2), 637-642 (2002).
100. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081), 237-241 (2006).
101. Yoneyama M, Kikuchi M, Matsumoto K et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175(5), 2851-2858 (2005).
102. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5(7), 730-737 (2004).
103. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440(7081), 228-232 (2006).
104. Agostini L, Martinon F, Burns K et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20(3), 319-325 (2004).
105. Mariathasan S, Newton K, Monack DM et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430(6996), 213-218 (2004).
106. Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5(9), 581-592 (2003).
107. Chamaillard M, Hashimoto M, Horie Y et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4(7), 702-707 (2003).
108. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278(11), 8869-8872 (2003).
109. Kruger B, Boger CA, Schroppel B et al. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation. Transpl. Int. 20(7), 600-607 (2007).
110. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24(1), 93-103 (2006).
111. Ishii KJ, Coban C, Kato H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7(1), 40-48 (2006).
112. Bogdan C, Mattner J, Schleicher U. The role of type I interferons in non-viral infections. Immunol. Rev. 202, 33-48 (2004).
113. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 5(9), 675-687 (2005).
114. Mancuso G, Midiri A, Biondo C et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178(5), 3126-3133 (2007).
115. Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res. 15(6), 407-422 (2005).
116. Stetson DB, Medzhitov R. Antiviral defense: interferons and beyond. J. Exp. Med. 203(8), 1837-1841 (2006).
117. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
118. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25(3), 361-372 (2006).
119. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4(10), 1009-1015 (2003).
120. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202(5), 637-650 (2005).
121. Nguyen KB, Watford WT, Salomon R et al. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297(5589), 2063-2066 (2002).
122. Nguyen KB, Salazar-Mather TP, Dalod MY et al. Coordinated and distinct roles for IFN-α β, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169(8), 4279-4287 (2002).
123. + T cells in vivo by IL-15. Immunity 8(5), 591-599 (1998).
124. Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant. 3(1), 74-78 (2003).
125. Tovey MG, Benizri E, Gugenheim J et al. Role of the type I interferons in allograft rejection. J. Leukoc. Biol. 59(4), 512-517 (1996).
126. Walter T, Dumortier J, Guillaud O et al. Rejection under α interferon therapy in liver transplant recipients. Am. J. Transplant. 7(1), 177-184 (2007).
127. Carbognin SJ, Solomon NM, Yeo FE et al. Acute renal allograft rejection following pegylated IFN-α treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am. J. Tansplant. 6(7), 1746-1751 (2006).
128. Gugenheim J, Tovey M, Gigou M et al. Prolongation of heart allograft survival in rats by interferon-specific antibodies and low dose cyclosporin A. Transpl. Int. 5(Suppl. 1), S460-S461 (1992).
129. Afifi MS, Kumar V, Bennett M. Stimulation of genetic resistance to marrow grafts in mice by interferon-α/β. J. Immunol. 134(6), 3739-3745 (1985).
130. Thornley TB, Phillips NE, eaudette-Zlatanova BC et al. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J. Immunol. 179(10), 6620-6629 (2007).
131. Zhang D, Zhang G, Hayden MS et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303(5663), 1522-1526 (2004).